Publications by authors named "Jia-Lei Zhong"
Introduction: Disitamab Vedotin (DV, RC48, or RC48-ADC) is a novel humanized antibody-drug conjugate (ADC), which is based on human epidermal growth factor receptor 2 antibody (anti-HER2, or hertuzumab) coupled with monomethyl auristatin E (MMAE). This study aims to evaluate the efficacy and safety of RC48-ADC in combination with programmed cell death protein 1 (PD-1) inhibitors for treatment of locally advanced or metastatic urothelial carcinoma (la/mUC) patients.
Patients And Methods: This is a retrospective and real-world investigation originated from an enrollment of locally advanced or mUC patients underwent treatments with RC48-ADC in combination with PD-1 inhibitors in two hospitals, between August 2022 and July 2024.
Article Synopsis
- - The study aims to explore the connection between proton pump inhibitors (PPIs) and overactive bladder (OAB) in adults, using data from the National Health and Nutrition Examination Survey from 2007-2018.
- - Researchers found that PPI users were more likely to experience OAB symptoms, such as nocturia and urge incontinence, with a significant increased risk of developing OAB over time.
- - The results suggest a clear association between prolonged PPI use and the likelihood of developing OAB, indicating that longer usage increases symptom frequency and severity.